ZA979599B - Humanized anti-CD11a antibodies - Google Patents

Humanized anti-CD11a antibodies

Info

Publication number
ZA979599B
ZA979599B ZA979599A ZA979599A ZA979599B ZA 979599 B ZA979599 B ZA 979599B ZA 979599 A ZA979599 A ZA 979599A ZA 979599 A ZA979599 A ZA 979599A ZA 979599 B ZA979599 B ZA 979599B
Authority
ZA
South Africa
Prior art keywords
humanized anti
cd11a antibodies
cd11a
antibodies
humanized
Prior art date
Application number
ZA979599A
Other languages
English (en)
Inventor
Paula M Jardieu
Leonard G Presta
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA979599B publication Critical patent/ZA979599B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA979599A 1996-11-27 1997-10-27 Humanized anti-CD11a antibodies ZA979599B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75720596A 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
ZA979599B true ZA979599B (en) 1999-04-28

Family

ID=25046834

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA979599A ZA979599B (en) 1996-11-27 1997-10-27 Humanized anti-CD11a antibodies

Country Status (17)

Country Link
EP (2) EP1516629B1 (cs)
JP (2) JP3778945B2 (cs)
KR (1) KR100532178B1 (cs)
AR (1) AR008919A1 (cs)
AT (1) ATE267257T1 (cs)
AU (1) AU731817C (cs)
CA (1) CA2272842C (cs)
DE (3) DE69729209T2 (cs)
DK (2) DK0941344T3 (cs)
ES (1) ES2221045T3 (cs)
FR (1) FR04C0028I2 (cs)
IL (3) IL130143A0 (cs)
LU (1) LU91122I2 (cs)
NL (1) NL300163I2 (cs)
PT (1) PT941344E (cs)
WO (1) WO1998023761A1 (cs)
ZA (1) ZA979599B (cs)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
ES2301254T3 (es) 1998-11-18 2008-06-16 Genentech, Inc. Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
US6652855B1 (en) * 1999-03-19 2003-11-25 Genentech, Inc. Treatment of LFA-1 associated disorders with increasing doses of LFA-1 antagonist
US6582698B1 (en) 1999-03-19 2003-06-24 Genentech, Inc. Treatment method
NZ519222A (en) * 1999-12-14 2004-04-30 Genentech Inc TNF-alpha antagonists and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
US7560275B2 (en) 1999-12-30 2009-07-14 Vbi Technologies, L.L.C. Compositions and methods for generating skin
US7575921B2 (en) 1999-12-30 2009-08-18 Vbi Technologies, L.L.C. Spore-like cells and uses thereof
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
DE60140457D1 (de) * 2000-09-01 2009-12-24 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
EP1472275B1 (en) 2002-02-05 2008-12-17 Genentech, Inc. Protein purification
ES2545067T3 (es) 2002-04-26 2015-09-08 Genentech, Inc. Purificación de proteínas basada en la no afinidad
WO2004024068A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
CA2523142A1 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
PL3095793T3 (pl) 2003-07-28 2020-09-07 Genentech, Inc. Redukcja wycieku białka A w trakcie chromatografii powinowactwa z białkiem A
US20060122377A1 (en) 2004-02-19 2006-06-08 Genentech, Inc. CDR-repaired antibodies
CA2554965C (en) 2004-02-19 2015-08-11 The Cbr Institute For Biomedical Research, Inc. Antibodies specific for activated conformation of lfa-1
RU2006146939A (ru) 2004-06-09 2008-07-20 Дженентек Способ лечения кольцевидной гранулемы или саркоида
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US20100267933A1 (en) 2006-12-21 2010-10-21 Moya Wilson Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
KR101431856B1 (ko) 2007-01-22 2014-08-27 제넨테크, 인크. 항체의 고분자전해질 침전 및 정제
CN101932591B (zh) 2007-07-09 2018-02-16 健泰科生物技术公司 在多肽的重组生产期间防止二硫键还原
KR20140015166A (ko) 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
KR101924831B1 (ko) 2008-04-09 2018-12-05 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
EP2145901B1 (en) 2008-07-18 2012-11-14 Technische Universität Braunschweig Recombinant anti-MUC1 antibodies
JP5666447B2 (ja) 2008-08-14 2015-02-12 ジェネンテック， インコーポレイテッド 常在性タンパク質置換イオン交換メンブレンクロマトグラフィを用いた混入物除去方法
CA2734275A1 (en) 2008-09-10 2010-03-18 Genentech, Inc. Compositions and methods for the prevention of oxidative degradation of proteins
EP2370561B1 (en) 2008-12-16 2019-08-07 EMD Millipore Corporation Stirred tank reactor and method
SG171764A1 (en) 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
IL264336B2 (en) 2009-08-11 2024-02-01 Genentech Inc Production of proteins in cell culture medium without glutamine
EP3736338A1 (en) 2009-09-01 2020-11-11 F. Hoffmann-La Roche AG Enhanced protein purification through a modified protein a elution
CN102762720B (zh) 2009-11-12 2015-03-11 Vbi技术有限责任公司 类孢子细胞子群及其用途
EP2531592A1 (en) 2010-02-04 2012-12-12 Vivalis Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
SI2550018T1 (sl) 2010-03-22 2019-05-31 F. Hoffmann-La Roche Ag Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2571903B1 (en) 2010-05-17 2019-09-04 EMD Millipore Corporation Stimulus responsive polymers for the purification of biomolecules
DK2576580T3 (en) 2010-05-28 2016-10-17 Hoffmann La Roche LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
CA3111727C (en) 2010-06-24 2022-07-26 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
WO2012021773A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012088272A1 (en) * 2010-12-21 2012-06-28 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012095514A1 (en) 2011-01-14 2012-07-19 Vivalis Recombinant protein production system
US10364268B2 (en) 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
JP6225162B2 (ja) 2012-03-27 2017-11-01 ジェネンテック， インコーポレイテッド 組換えタンパク質の改良された収集操作
SG10201709555SA (en) 2012-05-18 2017-12-28 Genentech Inc High-concentration monoclonal antibody formulations
CA2898146C (en) 2012-12-19 2020-12-01 Charles Andrew BOSWELL Methods and compositions for radiohalogen protein labeling
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
HRP20201404T1 (hr) 2013-07-16 2020-11-27 F. Hoffmann - La Roche Ag Postupci liječenja raka primjenom pd-1 osno vezujućeg antagonista i inhibitora tigita
RU2714759C2 (ru) 2014-07-09 2020-02-19 Дженентек, Инк. Корректировка ph для улучшения размораживания банков клеток
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
CN113956358A (zh) 2015-09-25 2022-01-21 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
BR112018070139A2 (pt) 2016-03-29 2019-02-05 Geltor Inc expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
AU2017382281B2 (en) 2016-12-22 2024-07-11 Genentech, Inc. Methods and formulations for reducing reconstitution time of lyophilized polypeptides
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
EP4368699A3 (en) 2018-07-03 2024-09-11 Bristol-Myers Squibb Company Methods of producing recombinant proteins
WO2020076776A1 (en) 2018-10-10 2020-04-16 Boehringer Ingelheim International Gmbh Method for membrane gas transfer in high density bioreactor culture
MX2021012032A (es) 2019-04-01 2021-11-03 Genentech Inc Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
KR20210151930A (ko) 2019-04-12 2021-12-14 젤터, 인코포레이티드 재조합 엘라스틴 및 이의 제조
CN114514311A (zh) 2019-08-01 2022-05-17 百时美施贵宝公司 改进补料分批细胞培养物中蛋白质产量的方法
EP4217383A1 (en) 2020-09-22 2023-08-02 Bristol-Myers Squibb Company Methods for producing therapeutic proteins
US20250115666A1 (en) 2021-08-05 2025-04-10 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life

Also Published As

Publication number Publication date
CA2272842A1 (en) 1998-06-04
NL300163I1 (nl) 2005-01-03
ES2221045T3 (es) 2004-12-16
FR04C0028I1 (cs) 2005-02-11
KR100532178B1 (ko) 2005-12-01
EP1516629B1 (en) 2013-04-03
CA2272842C (en) 2012-05-15
EP0941344B1 (en) 2004-05-19
IL130143A0 (en) 2000-06-01
DE69729209D1 (de) 2004-06-24
DE122004000047I1 (de) 2005-04-21
PT941344E (pt) 2004-10-29
JP2001505425A (ja) 2001-04-24
AR008919A1 (es) 2000-02-23
DE69729209T2 (de) 2005-05-19
LU91122I2 (fr) 2005-01-10
EP1516629A3 (en) 2006-09-27
IL175583A0 (en) 2006-09-05
NL300163I2 (nl) 2005-07-01
JP4309383B2 (ja) 2009-08-05
EP1516629A2 (en) 2005-03-23
JP3778945B2 (ja) 2006-05-24
WO1998023761A1 (en) 1998-06-04
DK1516629T3 (da) 2013-06-03
AU731817C (en) 2001-11-01
KR20000069147A (ko) 2000-11-25
AU4992997A (en) 1998-06-22
AU731817B2 (en) 2001-04-05
JP2006036779A (ja) 2006-02-09
IL130143A (en) 2006-08-01
DE122004000047I2 (de) 2006-06-14
EP0941344A1 (en) 1999-09-15
ATE267257T1 (de) 2004-06-15
FR04C0028I2 (cs) 2007-10-26
DK0941344T3 (da) 2004-09-27

Similar Documents

Publication Publication Date Title
ZA979599B (en) Humanized anti-CD11a antibodies
IL128406A0 (en) Monoclonal antibodies
GB9603256D0 (en) Antibodies
ZA959336B (en) Antibodies
PL311926A1 (en) Anti-alphav-integrinic monoclonal antibodies
ZA979185B (en) Anti-ErbB2 antibodies
PT837927E (pt) Anticorpos contra cd80
PL330111A1 (en) Concentyratyed antibody preparation
GB9809839D0 (en) Antibody
AU6702998A (en) Anti-alphabeta3 humanized monoclonal antibodies
GB9412166D0 (en) Retargetting antibodies
HUP9800744A3 (en) Antibodies against fas-antigene
EP0977590A4 (en) HUMAN MONOCLONAL ANTIBODIES
GB9818915D0 (en) Antibodies
HUP9901579A3 (en) Antibodies specific for alpha-d-integrin
GB9828700D0 (en) Antibody
GB9718911D0 (en) Monoclonal antibodies
GB9819411D0 (en) Antibodies
GB9710820D0 (en) Immunological method
GB9615027D0 (en) Monoclonal antibodies
GB9516137D0 (en) Antibodies
GB9406222D0 (en) Huminised antibodies
GB9406243D0 (en) Antibodies
GB9415331D0 (en) Antibodies
IL134049A0 (en) Anti-cryptdin antibodies